Spain

Grifols International

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

SPAIN Spain

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Grifols Starts Production of its Hyperimmune Immunoglobulin as a Potential Passive Immune Therapy Against COVID-19

Lead Product(s): Anti-SARS-CoV-2 hyperimmune globulin therapy

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 11, 2020

Details:

The company has started production of its anti-SARS-CoV-2 hyperimmune immunoglobulin with specific antibodies using the plasma of people who have overcome the disease. It is the first specific drug developed to combat COVID-19.

Sesderma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

SPAIN Spain

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Sesderma Labs Produces Lactyferrin to Counter the COVID-19 Strain

Lead Product(s): Genistein

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 10, 2020

Details:

More than 75 patients affected by COVID-19 have been successfully treated with Lactyferrin, to date with moderate to severe clinical features.

Archivel Farma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

SPAIN Spain

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Archivel Farma’s RUTI Vaccine to Start a Clinical Trial to Increase the Immunity of Healthcare Professionals Exposed to the Risk of COVID-...

Lead Product(s): RUTI vaccine

Therapeutic Area: Infections and Infectious Diseases Product Name: RUTI

Highest Development Status: Undisclosed Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 08, 2020

Details:

RUTI® vaccine is administered by subcutaneous injection, is safe and is in advanced clinical stages in India and Ukraine for the treatment of tuberculosis and antibiotic-resistant tuberculosis, and also as an enhancer of the anticancer response in bladder cancer patients.

Grifols International

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

SPAIN Spain

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Grifols Announces Formal Collaboration with US Government to Produce the First Treatment Specifically Targeting COVID-19

Lead Product(s): Anti-SARS-CoV-2 hyperimmune globulin therapy

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Large molecule

Partner/Sponsor/Collaborator: BARDA

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration March 25, 2020

Details:

Grifols will volunteer its expertise and resources in the areas of plasma collection using its network of plasma donor centers; test and qualify donors in conjunction with other health agencies.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Product Type

Companies

Grifols International

Grifols Starts Production of its Hyperimmune Immunoglobulin as a Potential Passive Immune Therapy Against COVID-19

Sesderma

Sesderma Labs Produces Lactyferrin to Counter the COVID-19 Strain

Archivel Farma

Archivel Farma’s RUTI Vaccine to Start a Clinical Trial to Increase the Immunity of Healthcare Professionals Exposed to the Risk of COVID-...

Grifols International

Grifols Announces Formal Collaboration with US Government to Produce the First Treatment Specifically Targeting COVID-19